Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All iSpecimen Inc. filings on SEC EDGAR ↗
For the nine months ended September 30, 2026, iSpecimen Inc. reported a net loss of $5.85 million on revenue of $551,983, a significant decrease from $1.88 million in revenue for the same period in 2025. The company strengthened its balance sheet through PIPE financings totaling $7.5 million and executed a 1-for-40 reverse stock split in April 2026.
iSpecimen Inc. entered into a securities purchase agreement with accredited investors for a private placement of 500 shares of Series D Convertible Preferred Stock at $800 per share. The offering generated gross proceeds of $400,000, which the company intends to use for working capital and general corporate purposes. E.F. Hutton & Co. served as the exclusive placement agent for the transaction.
iSpecimen Signs $4.5M M&A Deal with Foldlab AI Ltd.
iSpecimen Inc. completed the acquisition of AI software assets from Foldlab AI Ltd. for an aggregate purchase price of $4.5 million, consisting of $750,000 in cash, $1.25 million in milestone payments, and $2.5 million in common stock. The acquired assets include a Disease-Associated Protein Discovery AI Agent and a Disease Trend Prediction and Monitoring AI Model, marking the company's entry into AI-powered drug discovery.
iSpecimen Inc. stockholders approved an amendment to the company's Certificate of Incorporation to effect a reverse stock split. The approved ratio range is between 1-for-10 and 1-for-100, with the final ratio to be determined by the Board of Directors.
iSpecimen Inc. stockholders approved the acquisition of assets from Foldlab AI Ltd., which includes the issuance of common stock as partial consideration. The company also received approval for potential future equity issuances exceeding 19.99% of outstanding shares under Nasdaq rules, while the vote on a proposed reverse stock split was adjourned to October 30, 2026.